EMBIO Diagnostics named a Rising Star Winner across the Middle East & Cyprus by Deloitte

EMBIO Diagnostics named a Rising Star Winner across the Middle East & Cyprus by Deloitte  

EMBIO Diagnostics, a biotech company with an investment from ASBIS, has been recognized as a Rising Star Winner in the Deloitte Technology Fast 50 program for the Middle East & Cyprus. This recognition underscores the company’s commitment to pioneering and excellence in addressing issues regarding air and environmental monitoring and food safety through technology.   

Deloitte has been recognizing the achievements of the most rapidly expanding technology firms in North America, Asia-Pacific, and EMEA for over 20 years, including programs such as the Deloitte Technology Fast 500 and Fast 50. 

The Deloitte Middle East & Cyprus Technology Fast 50 Program aims to highlight the diverse range of innovation in the region. Up-and-coming and inspiring young companies will drive innovation that will have a substantial impact on the future economic landscape of the region. 

Remarkably, this marks the company’s second notable award since 2024. This year, EMBIO Diagnostics was acknowledged for its contributions and secured a spot in the Foodtech 500, a prestigious global list recognizing talent at the intersection of food, technology, and sustainability. 

About EMBIO Diagnostics

EMBIO Diagnostics is a fast-growing biotech firm specializing in the design and development of cutting-edge, portable, biosensor-based digital devices for swift diagnostics, using expertise in AI and machine learning. For more, please, visit https://embiodiagnostics.eu/